Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The purpose of this study was to confirm the efficacy and safety of twice-daily glycopyrrolate 15.6 µg, a long-acting muscarinic antagonist, in patients with stable, symptomatic, chronic obstructive pulmonary disease (COPD) with moderate-to-severe airflow limitation.
Methods: The GEM1 study was a 12-week, multicenter, double-blind, parallel-group, placebo-controlled study that randomized patients with stable, symptomatic COPD with moderate-to-severe airflow limitation to twice-daily glycopyrrolate 15.6 µg or placebo (1:1) via the Neohaler(®) device. The primary objective was to demonstrate superiority of glycopyrrolate versus placebo in terms of forced expiratory volume in 1 second area under the curve between 0 and 12 hours post morning dose at week 12. Other outcomes included additional spirometric end points, transition dyspnea index, St George's Respiratory Questionnaire, COPD Assessment Test, rescue medication use, and symptoms reported by patients via electronic diary. Safety was also assessed during the study.
Results: Of the 441 patients randomized (glycopyrrolate, n=222; placebo, n=219), 96% of patients completed the planned treatment phase. Glycopyrrolate demonstrated statistically significant (P<0.001) improvements in lung function versus placebo. Glycopyrrolate showed statistically significant improvement in the transition dyspnea index focal score, St George's Respiratory Questionnaire total score, COPD Assessment Test score, rescue medication use, and daily total symptom score versus placebo at week 12. Safety was comparable between the treatment groups.
Conclusion: Significant improvement in lung function, dyspnea, COPD symptoms, health status, and rescue medication use suggests that glycopyrrolate is a safe and effective treatment option as maintenance bronchodilator in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907493 | PMC |
| http://dx.doi.org/10.2147/COPD.S100445 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
To Study the Safety and Efficacy of Fixed Dose Combination of Indacaterolmaleate 110 µg + Glycopyrrinium 50 µg versus Tiotropium 9 µg + Formoterol 12 µg in Patients with Chronic Obstructive Airway Disease.
Ann Afr Med
July 2025
Department of Radiodiagnosis, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India.
Background: The efficacy and safety of once-daily fixed-dose combination of indacaterol maleate (IND) 110 µg with glycopyrronium 25 µg (GLY) via Rotahaler device versus tiotropium (TRP) 9 µg + formoterol (FOR) 112 µg was evaluated in patients with chronic obstructive airway disease.
Objective: (1) To study and compare the effect of inhaled IND/GLY (110/50 µg) once-daily (OD) fixed-dose combination versus FOR/TRP (9/12 µg) twice daily (BD) on lung function in chronic obstructive pulmonary disease (COPD) patients by evaluating forced expiratory volume in 1 s (FEV1), 1 h postinhalation on days 28 th , 56 th , and 84 th of the treatment. (2) To assess patient-reported outcomes (PROs) using COPD assessment test (CAT) scores, intake of rescue medications, and frequency of exacerbations.
Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study.
BMJ
December 2024
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02120, USA.
Objective: To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler, in patients with chronic obstructive pulmonary disease (COPD) treated in routine clinical practice.
Design: New user cohort study.
Setting: Longitudinal commercial US claims data.
Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data.
Adv Ther
February 2025
US Value Evidence and Outcomes, R&D Global Medical, GSK, Collegeville, PA, 19426-0989, USA.
Article Synopsis
- This study examines how well patients with chronic obstructive pulmonary disease (COPD) stick to their medication regimens, comparing a single daily inhaler (FF/UMEC/VI) to a combination that requires two inhalations twice a day (BUD/GLY/FOR).
- Using insurance claims data from 2019 to 2023, researchers evaluated adherence (how often patients take their medication) and persistence (how long they continue treatment), with a total of 11,597 COPD patients involved.
- Results showed that patients using the single inhaler (FF/UMEC/VI) had better adherence and persistence over 6 and 12 months compared to those using the combination
Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).
Am J Respir Crit Care Med
February 2025
AstraZeneca, Cambridge, United Kingdom.
Article Synopsis
- Chronic obstructive pulmonary disease (COPD) increases the risk of cardiovascular issues, and the ETHOS trial showed that triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) lowered the rates of exacerbations and all-cause mortality compared to dual therapies.
- The study aimed to evaluate the effects of BGF on cardiovascular events and the time to first severe exacerbation, finding that BGF 320 significantly reduced the occurrence of major adverse cardiac events and other serious cardiopulmonary issues when compared to dual therapy with glycopyrrolate/formoterol fumarate (GFF).
- Overall, BGF demonstrated a notable benefit in reducing
Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history.
Respir Res
August 2024
Late RIA, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Background: Japanese guidelines recommend triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) and no concurrent asthma diagnosis who experience frequent exacerbations and have blood eosinophil (EOS) count ≥ 300 cells/mm, and in patients with COPD and asthma with continuing/worsening symptoms despite receiving dual ICS/LABA therapy. These post-hoc analyses of the KRONOS study in patients with COPD and without an asthma diagnosis, examine the effects of fixed-dose triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) versus dual therapies on lung function and exacerbations based on blood EOS count - focusing on blood EOS count 100 to < 300 cells/mm - as a function of exacerbation history and COPD severity.
Methods: In KRONOS, patients were randomized to receive treatments that included BGF 320/14.